US Stock MarketDetailed Quotes
BTAI BioXcel Therapeutics
- 0.571
- -0.017-2.96%
Close Nov 21 16:00 ET
- 0.490
- -0.081-14.13%
Post 20:01 ET
24.39MMarket Cap-279P/E (TTM)
0.580High0.565Low195.08KVolume0.571Open0.588Pre Close105.49KTurnover0.56%Turnover RatioLossP/E (Static)42.75MShares4.17052wk High-0.28P/B19.77MFloat Cap0.50052wk Low--Dividend TTM34.65MShs Float71.500Historical High--Div YieldTTM2.57%Amplitude0.500Historical Low0.540Avg Price1Lot Size
BioXcel Therapeutics Key Stats
Quarterly+Annual
YOY
| (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | -37.24%214K | 141.58%1.1M | 182.52%582K | 268.00%1.38M | 57.98%376K | 148.91%341K | 457K | 206K | 375K | 238K |
| Operating revenue | -37.24%214K | 141.58%1.1M | 182.52%582K | 268.00%1.38M | 57.98%376K | 148.91%341K | --457K | --206K | --375K | --238K |
| Cost of revenue | 128.52%1.17M | 138.46%62K | 788.89%80K | 6,200.00%1.26M | 7,833.33%714K | 4,554.55%512K | 26K | 9K | 20K | 9K |
| Gross profit | -459.06%-956K | 141.76%1.04M | 154.82%502K | -66.20%120K | -247.60%-338K | -235.71%-171K | 431K | 197K | 355K | 229K |
| Operating expense | -70.92%12.78M | -66.92%17.48M | -52.01%24.67M | 4.84%167.74M | -63.22%19.54M | 12.39%43.96M | 45.63%52.85M | 63.26%51.4M | 49.62%160M | 103.29%53.12M |
| Selling and administrative expenses | -68.44%7.68M | -63.47%9.45M | -43.78%13.26M | 21.31%83.41M | -53.53%9.6M | 42.75%24.34M | 40.75%25.87M | 82.61%23.6M | 26.80%68.76M | 51.86%20.66M |
| -Selling and marketing expense | -76.92%1.06M | -95.59%305K | -66.44%872K | 6.93%19.9M | -85.26%1.43M | 67.90%4.6M | 9.46%6.91M | 281.50%2.6M | 520.09%18.61M | 600.65%9.67M |
| -General and administrative expense | -66.47%6.62M | -51.77%9.15M | -40.98%12.39M | 26.64%63.51M | -25.62%8.18M | 37.94%19.75M | 57.11%18.96M | 71.54%21M | -2.10%50.15M | -10.08%11M |
| Research and development costs | -74.00%5.1M | -70.22%8.03M | -58.99%11.4M | -7.58%84.33M | -69.40%9.93M | -11.07%19.62M | 50.64%26.97M | 49.79%27.8M | 73.10%91.24M | 159.15%32.46M |
| Operating profit | 68.87%-13.74M | 68.63%-16.44M | 52.80%-24.16M | -4.99%-167.62M | 62.42%-19.88M | -13.19%-44.13M | -44.44%-52.41M | -62.64%-51.2M | -49.29%-159.65M | -102.41%-52.89M |
| Net non-operating interest income expense | -45.33%-3.17M | -84.92%-3.03M | -96.75%-2.66M | -34.83%-7.67M | -73.57%-2.49M | 24.09%-2.18M | -18.52%-1.64M | -17,000.00%-1.35M | -142,225.00%-5.69M | -24,000.00%-1.43M |
| Non-operating interest income | -42.32%616K | -58.61%671K | -53.00%947K | 123.46%5.65M | -36.34%946K | 29.77%1.07M | 694.61%1.62M | 13,333.33%2.02M | 5,645.45%2.53M | --1.49M |
| Non-operating interest expense | 16.54%3.79M | 13.53%3.7M | 7.13%3.61M | 62.11%13.31M | 17.64%3.44M | -12.11%3.25M | 105.49%3.26M | 48,000.00%3.37M | 20,432.50%8.21M | --2.92M |
| Other net income (expense) | 178.31%3.26M | 1,980.07%11.17M | 113.01%32K | -782.67%-3.77M | 122.50%108K | -6,822.58%-4.17M | 537K | -246K | -427K | -480K |
| Special income (charges) | 62.70%-1.55M | ---856K | ---- | ---4.16M | --0 | ---4.16M | --0 | ---- | --0 | --0 |
| -Less：Restructuring and merger&acquisition | -62.70%1.55M | --856K | ---- | --4.16M | --0 | --4.16M | --0 | ---- | --0 | --0 |
| Other non- operating income (expenses) | 96,440.00%4.82M | 2,139.48%12.03M | 113.01%32K | 192.27%394K | 122.50%108K | -108.06%-5K | --537K | ---246K | ---427K | ---480K |
| Income before tax | 72.96%-13.65M | 84.49%-8.3M | 49.26%-26.79M | -8.02%-179.05M | 59.39%-22.26M | -20.77%-50.49M | -42.06%-53.52M | -67.76%-52.8M | -55.01%-165.76M | -109.78%-54.81M |
| Income tax | ||||||||||
| Net income | 72.96%-13.65M | 84.49%-8.3M | 49.26%-26.79M | -8.02%-179.05M | 59.39%-22.26M | -20.77%-50.49M | -42.06%-53.52M | -67.76%-52.8M | -55.01%-165.76M | -109.78%-54.81M |
| Net income continuous Operations | 72.96%-13.65M | 84.49%-8.3M | 49.26%-26.79M | -8.02%-179.05M | 59.39%-22.26M | -20.77%-50.49M | -42.06%-53.52M | -67.76%-52.8M | -55.01%-165.76M | -109.78%-54.81M |
| Minority interest income | ||||||||||
| Net income attributable to the parent company | 72.96%-13.65M | 84.49%-8.3M | 49.26%-26.79M | -8.02%-179.05M | 59.39%-22.26M | -20.77%-50.49M | -42.06%-53.52M | -67.76%-52.8M | -55.01%-165.76M | -109.79%-54.81M |
| Preferred stock dividends | ||||||||||
| Other preferred stock dividends | ||||||||||
| Net income attributable to common stockholders | 72.96%-13.65M | 84.49%-8.3M | 49.26%-26.79M | -8.02%-179.05M | 59.39%-22.26M | -20.77%-50.49M | -42.06%-53.52M | -67.76%-52.8M | -55.01%-165.76M | -109.79%-54.81M |
| Basic earnings per share | 81.40%-0.32 | 88.52%-0.21 | 52.72%-0.87 | -3.89%-6.15 | 61.03%-0.76 | -15.44%-1.72 | -35.56%-1.83 | -64.29%-1.84 | -46.17%-5.92 | -109.68%-1.95 |
| Diluted earnings per share | 81.40%-0.32 | 88.52%-0.21 | 52.72%-0.87 | -3.89%-6.15 | 61.03%-0.76 | -15.44%-1.72 | -35.56%-1.83 | -64.29%-1.84 | -46.17%-5.92 | -109.68%-1.95 |
| Dividend per share | ||||||||||
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
No Data